OA05.06 Early Diagnosis of Lung Cancer Among Younger vs. Older Adults: Widening Disparities in the Era of Lung Cancer Screening

Potter, A.; Senthil, P.; Mansur, A.; Mathey-Andrews, C.; Auchincloss, H.; Yang, C.-F.J.

doi:10.1016/j.jtho.2022.07.034

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among screening-eligible persons nationally, we found that that UTD-LCS prevalence was higher among older persons than among younger persons, a finding consistent with other studies . As evidence emerges of shifting late-stage diagnosis burden to younger ages, this finding suggests the need for targeted demand (eg, education campaigns) and delivery (eg, addressing lower health care coverage, leveraging allied health professionals) interventions among younger LCS-eligible persons. Conversely, after adjusting for age, we observed higher UTD-LCS prevalence with increasing number of comorbidities.…”

Section: Discussionsupporting

confidence: 89%

Lung Cancer Screening in the US, 2022

Bandi,

Star,

Ashad-Bishop

et al. 2024

JAMA Intern Med

View full text Add to dashboard Cite

ImportanceThe US Preventive Services Task Force (USPSTF) recommends annual lung cancer screening (LCS) with low-dose computed tomography in high-risk individuals (age 50-80 years, ≥20 pack-years currently smoking or formerly smoked, and quit &lt;15 years ago) for early detection of LC. However, representative state-level LCS data are unavailable nationwide.ObjectiveTo estimate the contemporary prevalence of up-to-date (UTD) LCS in the US nationwide and across the 50 states and the District of Columbia.Design, Setting, and ParticipantsThis cross-sectional study used data from the 2022 Behavioral Risk Factor Surveillance System (BRFSS) population-based, nationwide, state-representative survey for respondents aged 50 to 79 years who were eligible for LCS according to the 2021 USPSTF eligibility criteria. Data analysis was performed from October 1, 2023, to March 20, 2024.Main Outcomes and MeasuresThe main outcome was self-reported UTD-LCS (defined as past-year) prevalence according to the 2021 USPSTF eligibility criteria in respondents aged 50 to 79 years. Adjusted prevalence ratios (APRs) and 95% CIs compared differences.ResultsAmong 25 958 sample respondents eligible for LCS (median [IQR] age, 62 [11] years), 61.5% reported currently smoking, 54.4% were male, 64.4% were aged 60 years or older, and 53.0% had a high school education or less. The UTD-LCS prevalence was 18.1% overall, but varied across states (range, 9.7%-31.0%), with relatively lower levels in southern states characterized by high LC mortality burden. The UTD-LCS prevalence increased with age (50-54 years: 6.7%; 70-79 years: 27.1%) and number of comorbidities (≥3: 24.6%; none: 8.7%). A total of 3.7% of those without insurance and 5.1% of those without a usual source of care were UTD with LCS, but state-level Medicaid expansions (APR, 2.68; 95% CI, 1.30-5.53) and higher screening capacity levels (high vs low: APR, 1.93; 95% CI, 1.36-2.75) were associated with higher UTD-LCS prevalence.Conclusions and RelevanceThis study of data from the 2022 BRFSS found that the overall prevalence of UTD-LCS was low. Disparities were largest according to health care access and geographically across US states, with low prevalence in southern states with high LC burden. The findings suggest that state-based initiatives to expand access to health care and screening facilities may be associated with improved LCS rates and reduced disparities.

show abstract

Section: Discussionsupporting

confidence: 89%